CDK4 and breast cancer: Despite the fact that the new guidelines for the therapy of advanced breast cancer includes a CDK4/6 inhibitor combined with endocrine treatment as the first- or second-line drug in most countries, most patients eventually develop acquired drug resistance to CDK4/6 inhibitors (Konecny et al., 2011).